TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.03% | -42.94% | -70.15% | -86.62% | -44.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.03% | -42.94% | -70.15% | -86.62% | -44.71% |
| Cost of Revenue | 38.59% | 33.87% | 64.21% | 68.50% | -81.41% |
| Gross Profit | -117.56% | -1,538.42% | -160.47% | -111.17% | 91.05% |
| SG&A Expenses | 18.29% | 23.22% | 24.03% | 14.92% | 7.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.94% | 22.14% | 23.28% | 20.20% | 19.64% |
| Operating Income | -24.44% | -29.25% | -36.84% | -44.26% | -31.64% |
| Income Before Tax | -28.12% | -30.99% | -35.83% | -42.91% | -26.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.12% | -30.99% | -35.83% | -42.91% | -26.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.12% | -30.99% | -35.83% | -42.91% | -26.01% |
| EBIT | -24.44% | -29.25% | -36.84% | -44.26% | -31.64% |
| EBITDA | -27.03% | -32.32% | -40.42% | -48.37% | -34.75% |
| EPS Basic | -14.51% | -15.53% | -17.97% | -3.80% | 18.58% |
| Normalized Basic EPS | -13.62% | -14.62% | -17.01% | -2.98% | 18.58% |
| EPS Diluted | -14.51% | -15.53% | -17.97% | -3.80% | 18.58% |
| Normalized Diluted EPS | -13.62% | -14.62% | -17.01% | -2.98% | 18.58% |
| Average Basic Shares Outstanding | 12.20% | 13.64% | 15.05% | 26.15% | 40.94% |
| Average Diluted Shares Outstanding | 12.20% | 13.64% | 15.05% | 26.15% | 40.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |